A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
收藏DataCite Commons2024-11-27 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003716/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
提供机构：
Vivli
创建时间：
2019-04-12
